_id
69130306ccc777a4e85d79db
Ticker
IPSEF
Name
Ipsen S.A
Exchange
PINK
Address
70 rue Balard, Paris, France, 75015
Country
USA
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Currency
USD
Website
https://www.ipsen.com
Description
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a inhibitor that is in phase III clinical trial for the treatment of second line follicular lymphoma; Tovorafenib that is in phase III clinical trial to treat first line pediatric Low-Grade Gliomas and is In phase II clinical trial for the treatment of relapsed/refractory pediatric Low-Grade Gliomas; and IPN01194 and IPN01195 that is in phase I to treat solid tumors. The company is also developing products for rare disease comprising Bylvay for the treatment of progressive familial intrahepatic cholestasis; Iqirvo, a peroxisome proliferator-activated receptor agonist to treat primary biliary cholangitis; NutropinAq, a liquid formulation of recombinant human growth hormone; Increlex, a recombinant human insulin-like growth factor; Fidrisertib that is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressive; Ritivixibat that is in phase II clinical trial to treat primary sclerosing cholangitis. In addition, it develops neuroscience products, such as Dysport that is in phase III clinical trial for the treatment of chronic and episodic migraine; and IPN10200 that is in phase II to treat aesthetic and therapeutic indications. The company has a partnership with Simcere Zaiming Pharmaceutical Co., Ltd. for the development of SIM0613, a protein expressed on varies tumor types and cancer-associated fibroblasts. The company was founded in 1929 and is headquartered in Paris, France.
Last Close
113.13
Volume
-
Current Price
113.13
Change
0
Last Updated
2026-01-04T15:21:56.576Z
Image
data:image/webp;base64,UklGRrwBAABXRUJQVlA4ILABAACQCQCdASpAAEAAPrVYo00nJaMiJBgMAOAWiUAZ/DXeMCbLWjtpsm+e6pXGPy6vC/893CldLNgcgjhS+ulTd40YnzYNvopbxjoE7GlhYuvjc7opa/wAAP73fi/9Xfnb9T3seMJpJARbpkUjit4dnEXjhNx7+DT14ZG+j4NnzaNbil8SxiHv31NU0g0s0Yrj+C6EZ442ydbFwX9anc6IAYhT4PHWoE/+EJv9kcvwMP+opmYJnVNaRXxbo5qmq2F4qSwf3+wzZBkUiyj9v7NaMZxRakwS+mEmeyI5XJ5bWHmOS3DOy1SdcbvqmGGTssdgoKWnan/kSis4rXCILyCaF2NIr5XsOHBiXr0Ss7vfyKyDzQ57tic8F1B547w8EPOCYiLRvKmK/PX85wq727SQeCa8Uo37WmiuO9aeBtdrK1Raxz4yu0+6hOPuLno0643CCzBTu/192HvZe1NR+N6L/VkP9u9+mMB5Q3G98N6TADjbQ81S7mI0Mdz1ED4HaIBuD+Smrl0iIuqTp3Dus8/uI3Opvclr4ajNiVnnzbn8rtY6QaSMoyqyKk02YRHH2qpAAAA=
Ipo Date
-
Market Cap
9322147840
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.8275714285714285
Sentiment Sources
7
Current Quarter
2025-06-30
Revenue
2143706202
Cost Of Revenue
382964549
Gross Profit
1760741653
Operating Expenses
1006239058
Operating Income
754502595
Interest Expense
18494443
Pretax Income
500645750
Net Income
393448660
Eps
4.71196
Dividends Per Share
136882438
Shares Outstanding
82402087
Income Tax Expense
105430105
EBITDA
750379630
Operating Margin
35.19617540389054
Total Other Income Expense Net
-253856845
Cash
1445000000
Short Term Investments
1800000
Receivables
746800000
Inventories
253600000
Total Current Assets
2814100000
Property Plant Equipment
665300000
Total Assets
6830500000
Payables
852000000
Short Term Debt
33600000
Long Term Debt
745600000
Total Liabilities
2600100000
Equity
4229100000
Bs_currency_symbol
EUR
Depreciation
191400000
Change In Working Capital
-38402474
Cash From Operations
620447333
Capital Expenditures
65142847
Cash From Investing
-156554871
Cash From Financing
417833053
Net Change In Cash
1000212868
Cf_currency_symbol
-
PE
18.0719
PB
2.2336560970419237
ROE
9.303366200846517
ROA
5.760173632969768
FCF
555304486
Fcf Percent
0.25903945488515223
Piotroski FScore
4
Health Score
78
Deep Value Investing Score
5.5
Defensive Investing Score
6.5
Dividend Investing Score
3.5
Economic Moat Investing Score
7.5
Garp Investing Score
6
Growth Investing Score
5
Momentum Investing Score
3.5
Net Net Investing Score
2.5
Quality Investing Score
7.5
Value Investing Score
6.5
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
2143706202
Quarters > 0 > income Statement > cost Of Revenue
382964549
Quarters > 0 > income Statement > gross Profit
1760741653
Quarters > 0 > income Statement > operating Expenses
1006239058
Quarters > 0 > income Statement > operating Income
754502595
Quarters > 0 > income Statement > interest Expense
18494443
Quarters > 0 > income Statement > pretax Income
500645750
Quarters > 0 > income Statement > net Income
393448660
Quarters > 0 > income Statement > eps
4.71196
Quarters > 0 > income Statement > dividends Per Share
136882438
Quarters > 0 > income Statement > shares Outstanding
83500000
Quarters > 0 > income Statement > income Tax Expense
105430105
Quarters > 0 > income Statement > EBITDA
750379630
Quarters > 0 > income Statement > operating Margin
35.19617540389054
Quarters > 0 > income Statement > total Other Income Expense Net
-253856845
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
1445000000
Quarters > 0 > balance Sheet > short Term Investments
1800000
Quarters > 0 > balance Sheet > receivables
746800000
Quarters > 0 > balance Sheet > inventories
253600000
Quarters > 0 > balance Sheet > total Current Assets
2814100000
Quarters > 0 > balance Sheet > property Plant Equipment
665300000
Quarters > 0 > balance Sheet > total Assets
6830500000
Quarters > 0 > balance Sheet > payables
852000000
Quarters > 0 > balance Sheet > short Term Debt
33600000
Quarters > 0 > balance Sheet > long Term Debt
745600000
Quarters > 0 > balance Sheet > total Liabilities
2600100000
Quarters > 0 > balance Sheet > equity
4229100000
Quarters > 0 > balance Sheet > currency_symbol
EUR
Quarters > 0 > cash Flow > net Income
334000000
Quarters > 0 > cash Flow > depreciation
191400000
Quarters > 0 > cash Flow > change In Working Capital
-38402474
Quarters > 0 > cash Flow > cash From Operations
620447333
Quarters > 0 > cash Flow > capital Expenditures
65142847
Quarters > 0 > cash Flow > cash From Investing
-156554871
Quarters > 0 > cash Flow > cash From Financing
417833053
Quarters > 0 > cash Flow > net Change In Cash
1000212868
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
4.71196
Quarters > 0 > ratios > PB
2.2336560970419237
Quarters > 0 > ratios > ROE
9.303366200846517
Quarters > 0 > ratios > ROA
5.760173632969768
Quarters > 0 > ratios > FCF
555304486
Quarters > 0 > ratios > Piotroski FScore
4
Quarters > 0 > ratios > fcf Percent
0.25903945488515223
Quarters > 0 > health Score
78
Quarters > 1 > quarter
2024-12-31
Quarters > 1 > income Statement > revenue
2698600000
Quarters > 1 > income Statement > cost Of Revenue
460350000
Quarters > 1 > income Statement > gross Profit
2238250000
Quarters > 1 > income Statement > operating Expenses
1900450000
Quarters > 1 > income Statement > operating Income
337800000
Quarters > 1 > income Statement > interest Expense
12900000
Quarters > 1 > income Statement > pretax Income
287450000
Quarters > 1 > income Statement > net Income
229900000
Quarters > 1 > income Statement > eps
2.754836220433247
Quarters > 1 > income Statement > dividends Per Share
200000
Quarters > 1 > income Statement > shares Outstanding
83453237
Quarters > 1 > income Statement > income Tax Expense
51300000
Quarters > 1 > income Statement > EBITDA
920450000
Quarters > 1 > income Statement > operating Margin
12.517601719410065
Quarters > 1 > income Statement > total Other Income Expense Net
-50350000
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
678100000
Quarters > 1 > balance Sheet > short Term Investments
1100000
Quarters > 1 > balance Sheet > receivables
697200000
Quarters > 1 > balance Sheet > inventories
285500000
Quarters > 1 > balance Sheet > total Current Assets
2021200000
Quarters > 1 > balance Sheet > property Plant Equipment
664200000
Quarters > 1 > balance Sheet > total Assets
6439000000
Quarters > 1 > balance Sheet > payables
854800000
Quarters > 1 > balance Sheet > short Term Debt
37200000
Quarters > 1 > balance Sheet > long Term Debt
287500000
Quarters > 1 > balance Sheet > total Liabilities
2257200000
Quarters > 1 > balance Sheet > equity
4181600000
Quarters > 1 > balance Sheet > currency_symbol
EUR
Quarters > 1 > cash Flow > net Income
125300000
Quarters > 1 > cash Flow > depreciation
520900000
Quarters > 1 > cash Flow > change In Working Capital
79600000
Quarters > 1 > cash Flow > cash From Operations
449500000
Quarters > 1 > cash Flow > capital Expenditures
723200000
Quarters > 1 > cash Flow > cash From Investing
-477500000
Quarters > 1 > cash Flow > cash From Financing
218200000
Quarters > 1 > cash Flow > net Change In Cash
192200000
Quarters > 1 > cash Flow > currency_symbol
-
Quarters > 1 > ratios > PE
2.754836220433247
Quarters > 1 > ratios > PB
2.257763703321695
Quarters > 1 > ratios > ROE
5.497895542376123
Quarters > 1 > ratios > ROA
3.570430191023451
Quarters > 1 > ratios > FCF
-273700000
Quarters > 1 > ratios > Piotroski FScore
4
Quarters > 1 > ratios > fcf Percent
-0.101422960053361
Quarters > 1 > health Score
55
Quarters > 2 > quarter
2024-06-30
Quarters > 2 > income Statement > revenue
875900000
Quarters > 2 > income Statement > cost Of Revenue
158350000
Quarters > 2 > income Statement > gross Profit
717550000
Quarters > 2 > income Statement > operating Expenses
558650000
Quarters > 2 > income Statement > operating Income
158900000
Quarters > 2 > income Statement > interest Expense
10900000
Quarters > 2 > income Statement > pretax Income
144750000
Quarters > 2 > income Statement > net Income
116000000
Quarters > 2 > income Statement > eps
1.3900000068301726
Quarters > 2 > income Statement > dividends Per Share
99800000
Quarters > 2 > income Statement > shares Outstanding
83453237
Quarters > 2 > income Statement > income Tax Expense
23600000
Quarters > 2 > income Statement > EBITDA
240850000
Quarters > 2 > income Statement > operating Margin
18.141340335654753
Quarters > 2 > income Statement > total Other Income Expense Net
-14150000
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
485400000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
719200000
Quarters > 2 > balance Sheet > inventories
272700000
Quarters > 2 > balance Sheet > total Current Assets
1899800000
Quarters > 2 > balance Sheet > property Plant Equipment
594200000
Quarters > 2 > balance Sheet > total Assets
6547200000
Quarters > 2 > balance Sheet > payables
857600000
Quarters > 2 > balance Sheet > short Term Debt
135100000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
2501100000
Quarters > 2 > balance Sheet > equity
4046900000
Quarters > 2 > balance Sheet > currency_symbol
-
Quarters > 2 > cash Flow > net Income
232000000
Quarters > 2 > cash Flow > depreciation
185000000
Quarters > 2 > cash Flow > change In Working Capital
-134100000
Quarters > 2 > cash Flow > cash From Operations
466000000
Quarters > 2 > cash Flow > capital Expenditures
59300000
Quarters > 2 > cash Flow > cash From Investing
-199100000
Quarters > 2 > cash Flow > cash From Financing
-318200000
Quarters > 2 > cash Flow > net Change In Cash
467500000
Quarters > 2 > cash Flow > currency_symbol
-
Quarters > 2 > ratios > PE
1.3900000068301726
Quarters > 2 > ratios > PB
2.3329127731868837
Quarters > 2 > ratios > ROE
2.8663915589710642
Quarters > 2 > ratios > ROA
1.7717497556207236
Quarters > 2 > ratios > FCF
406700000
Quarters > 2 > ratios > Piotroski FScore
4
Quarters > 2 > ratios > fcf Percent
0.4643224112341591
Quarters > 2 > health Score
69
Quarters > 3 > quarter
2024-03-31
Quarters > 3 > income Statement > revenue
-
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
-
Quarters > 3 > income Statement > operating Expenses
-
Quarters > 3 > income Statement > operating Income
-
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-
Quarters > 3 > income Statement > net Income
-
Quarters > 3 > income Statement > eps
-
Quarters > 3 > income Statement > dividends Per Share
49900000
Quarters > 3 > income Statement > shares Outstanding
82704606
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
-
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
485400000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
719200000
Quarters > 3 > balance Sheet > inventories
272700000
Quarters > 3 > balance Sheet > total Current Assets
1899800000
Quarters > 3 > balance Sheet > property Plant Equipment
594200000
Quarters > 3 > balance Sheet > total Assets
6547200000
Quarters > 3 > balance Sheet > payables
857600000
Quarters > 3 > balance Sheet > short Term Debt
135100000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
2501100000
Quarters > 3 > balance Sheet > equity
4046900000
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
116000000
Quarters > 3 > cash Flow > depreciation
92500000
Quarters > 3 > cash Flow > change In Working Capital
-67050000
Quarters > 3 > cash Flow > cash From Operations
233000000
Quarters > 3 > cash Flow > capital Expenditures
29650000
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
-159100000
Quarters > 3 > cash Flow > net Change In Cash
-26000000
Quarters > 3 > cash Flow > currency_symbol
-
Quarters > 3 > ratios > PE
-
Quarters > 3 > ratios > PB
2.3119849951271343
Quarters > 3 > ratios > ROE
-
Quarters > 3 > ratios > ROA
-
Quarters > 3 > ratios > FCF
203350000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
57
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
3574500000
Annuals > 0 > income Statement > cost Of Revenue
618700000
Annuals > 0 > income Statement > gross Profit
2955800000
Annuals > 0 > income Statement > operating Expenses
2459100000
Annuals > 0 > income Statement > operating Income
496700000
Annuals > 0 > income Statement > interest Expense
23800000
Annuals > 0 > income Statement > pretax Income
432200000
Annuals > 0 > income Statement > net Income
345900000
Annuals > 0 > income Statement > eps
4.144836227263419
Annuals > 0 > income Statement > dividends Per Share
99600000
Annuals > 0 > income Statement > shares Outstanding
83453237
Annuals > 0 > income Statement > income Tax Expense
74900000
Annuals > 0 > income Statement > EBITDA
1161300000
Annuals > 0 > income Statement > operating Margin
13.895649741222549
Annuals > 0 > income Statement > total Other Income Expense Net
-64500000
Annuals > 0 > income Statement > currency_symbol
EUR
Annuals > 0 > balance Sheet > cash
678100000
Annuals > 0 > balance Sheet > short Term Investments
1100000
Annuals > 0 > balance Sheet > receivables
697200000
Annuals > 0 > balance Sheet > inventories
285500000
Annuals > 0 > balance Sheet > total Current Assets
2021200000
Annuals > 0 > balance Sheet > property Plant Equipment
664200000
Annuals > 0 > balance Sheet > total Assets
6439000000
Annuals > 0 > balance Sheet > payables
854800000
Annuals > 0 > balance Sheet > short Term Debt
37200000
Annuals > 0 > balance Sheet > long Term Debt
287500000
Annuals > 0 > balance Sheet > total Liabilities
2257200000
Annuals > 0 > balance Sheet > equity
4181600000
Annuals > 0 > balance Sheet > currency_symbol
EUR
Annuals > 0 > cash Flow > net Income
357300000
Annuals > 0 > cash Flow > depreciation
705900000
Annuals > 0 > cash Flow > change In Working Capital
-54500000
Annuals > 0 > cash Flow > cash From Operations
915500000
Annuals > 0 > cash Flow > capital Expenditures
782500000
Annuals > 0 > cash Flow > cash From Investing
-676600000
Annuals > 0 > cash Flow > cash From Financing
-100000000
Annuals > 0 > cash Flow > net Change In Cash
158100000
Annuals > 0 > cash Flow > currency_symbol
EUR
Annuals > 0 > ratios > PE
4.144836227263419
Annuals > 0 > ratios > PB
2.257763703321695
Annuals > 0 > ratios > ROE
8.271953319303616
Annuals > 0 > ratios > ROA
5.371952166485479
Annuals > 0 > ratios > FCF
133000000
Annuals > 0 > ratios > Piotroski FScore
4
Annuals > 0 > ratios > fcf Percent
0.037208001119037624
Annuals > 0 > health Score
61
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
3306400000
Annuals > 1 > income Statement > cost Of Revenue
571200000
Annuals > 1 > income Statement > gross Profit
2735200000
Annuals > 1 > income Statement > operating Expenses
1919200000
Annuals > 1 > income Statement > operating Income
816000000
Annuals > 1 > income Statement > interest Expense
37700000
Annuals > 1 > income Statement > pretax Income
756100000
Annuals > 1 > income Statement > net Income
644400000
Annuals > 1 > income Statement > eps
7.728915879698153
Annuals > 1 > income Statement > dividends Per Share
99600000
Annuals > 1 > income Statement > shares Outstanding
83375212
Annuals > 1 > income Statement > income Tax Expense
136200000
Annuals > 1 > income Statement > EBITDA
887100000
Annuals > 1 > income Statement > operating Margin
24.679409629808855
Annuals > 1 > income Statement > total Other Income Expense Net
-59900000
Annuals > 1 > income Statement > currency_symbol
EUR
Annuals > 1 > balance Sheet > cash
528400000
Annuals > 1 > balance Sheet > short Term Investments
10600000
Annuals > 1 > balance Sheet > receivables
631300000
Annuals > 1 > balance Sheet > inventories
289500000
Annuals > 1 > balance Sheet > total Current Assets
1898400000
Annuals > 1 > balance Sheet > property Plant Equipment
574600000
Annuals > 1 > balance Sheet > total Assets
6322900000
Annuals > 1 > balance Sheet > payables
771400000
Annuals > 1 > balance Sheet > short Term Debt
36400000
Annuals > 1 > balance Sheet > long Term Debt
269700000
Annuals > 1 > balance Sheet > total Liabilities
2499100000
Annuals > 1 > balance Sheet > equity
3825100000
Annuals > 1 > balance Sheet > currency_symbol
EUR
Annuals > 1 > cash Flow > net Income
617100000
Annuals > 1 > cash Flow > depreciation
87900000
Annuals > 1 > cash Flow > change In Working Capital
76100000
Annuals > 1 > cash Flow > cash From Operations
865900000
Annuals > 1 > cash Flow > capital Expenditures
182900000
Annuals > 1 > cash Flow > cash From Investing
-1078200000
Annuals > 1 > cash Flow > cash From Financing
-435800000
Annuals > 1 > cash Flow > net Change In Cash
-646000000
Annuals > 1 > cash Flow > currency_symbol
EUR
Annuals > 1 > ratios > PE
7.728915879698153
Annuals > 1 > ratios > PB
2.465880038053907
Annuals > 1 > ratios > ROE
16.846618389061724
Annuals > 1 > ratios > ROA
10.191526040266334
Annuals > 1 > ratios > FCF
683000000
Annuals > 1 > ratios > Piotroski FScore
4
Annuals > 1 > ratios > fcf Percent
0.20656907815146383
Annuals > 1 > health Score
88
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
3156500000
Annuals > 2 > income Statement > cost Of Revenue
527700000
Annuals > 2 > income Statement > gross Profit
2628800000
Annuals > 2 > income Statement > operating Expenses
1757500000
Annuals > 2 > income Statement > operating Income
729900000
Annuals > 2 > income Statement > interest Expense
18500000
Annuals > 2 > income Statement > pretax Income
706100000
Annuals > 2 > income Statement > net Income
648600000
Annuals > 2 > income Statement > eps
7.805256562309167
Annuals > 2 > income Statement > dividends Per Share
99300000
Annuals > 2 > income Statement > shares Outstanding
83097845
Annuals > 2 > income Statement > income Tax Expense
112300000
Annuals > 2 > income Statement > EBITDA
937900000
Annuals > 2 > income Statement > operating Margin
23.123712973229843
Annuals > 2 > income Statement > total Other Income Expense Net
-23800000
Annuals > 2 > income Statement > currency_symbol
EUR
Annuals > 2 > balance Sheet > cash
1169300000
Annuals > 2 > balance Sheet > short Term Investments
31000000
Annuals > 2 > balance Sheet > receivables
632500000
Annuals > 2 > balance Sheet > inventories
284100000
Annuals > 2 > balance Sheet > total Current Assets
2397600000
Annuals > 2 > balance Sheet > property Plant Equipment
581400000
Annuals > 2 > balance Sheet > total Assets
5607900000
Annuals > 2 > balance Sheet > payables
647100000
Annuals > 2 > balance Sheet > short Term Debt
31500000
Annuals > 2 > balance Sheet > long Term Debt
581800000
Annuals > 2 > balance Sheet > total Liabilities
2271200000
Annuals > 2 > balance Sheet > equity
3337300000
Annuals > 2 > balance Sheet > currency_symbol
EUR
Annuals > 2 > cash Flow > net Income
592100000
Annuals > 2 > cash Flow > depreciation
336500000
Annuals > 2 > cash Flow > change In Working Capital
-39100000
Annuals > 2 > cash Flow > cash From Operations
971400000
Annuals > 2 > cash Flow > capital Expenditures
252900000
Annuals > 2 > cash Flow > cash From Investing
-458600000
Annuals > 2 > cash Flow > cash From Financing
-164200000
Annuals > 2 > cash Flow > net Change In Cash
356400000
Annuals > 2 > cash Flow > currency_symbol
EUR
Annuals > 2 > ratios > PE
7.805256562309167
Annuals > 2 > ratios > PB
2.8169056437389504
Annuals > 2 > ratios > ROE
19.43487250172295
Annuals > 2 > ratios > ROA
11.565826780078105
Annuals > 2 > ratios > FCF
718500000
Annuals > 2 > ratios > Piotroski FScore
4
Annuals > 2 > ratios > fcf Percent
0.22762553461111992
Annuals > 2 > health Score
90
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
2999100000
Annuals > 3 > income Statement > cost Of Revenue
538000000
Annuals > 3 > income Statement > gross Profit
2461100000
Annuals > 3 > income Statement > operating Expenses
1582800000
Annuals > 3 > income Statement > operating Income
849500000
Annuals > 3 > income Statement > interest Expense
23700000
Annuals > 3 > income Statement > pretax Income
814400000
Annuals > 3 > income Statement > net Income
646600000
Annuals > 3 > income Statement > eps
7.7568643150723595
Annuals > 3 > income Statement > dividends Per Share
82900000
Annuals > 3 > income Statement > shares Outstanding
83358426
Annuals > 3 > income Statement > income Tax Expense
168200000
Annuals > 3 > income Statement > EBITDA
1059300000
Annuals > 3 > income Statement > operating Margin
28.325164215931448
Annuals > 3 > income Statement > total Other Income Expense Net
-35500000
Annuals > 3 > income Statement > currency_symbol
EUR
Annuals > 3 > balance Sheet > cash
814700000
Annuals > 3 > balance Sheet > short Term Investments
42400000
Annuals > 3 > balance Sheet > receivables
564300000
Annuals > 3 > balance Sheet > inventories
219400000
Annuals > 3 > balance Sheet > total Current Assets
1953800000
Annuals > 3 > balance Sheet > property Plant Equipment
647500000
Annuals > 3 > balance Sheet > total Assets
5006800000
Annuals > 3 > balance Sheet > payables
594700000
Annuals > 3 > balance Sheet > short Term Debt
35300000
Annuals > 3 > balance Sheet > long Term Debt
562800000
Annuals > 3 > balance Sheet > total Liabilities
2252800000
Annuals > 3 > balance Sheet > equity
2751500000
Annuals > 3 > balance Sheet > currency_symbol
EUR
Annuals > 3 > cash Flow > net Income
646700000
Annuals > 3 > cash Flow > depreciation
237000000
Annuals > 3 > cash Flow > change In Working Capital
-32200000
Annuals > 3 > cash Flow > cash From Operations
909200000
Annuals > 3 > cash Flow > capital Expenditures
427700000
Annuals > 3 > cash Flow > cash From Investing
-344200000
Annuals > 3 > cash Flow > cash From Financing
-401200000
Annuals > 3 > cash Flow > net Change In Cash
169500000
Annuals > 3 > cash Flow > currency_symbol
EUR
Annuals > 3 > ratios > PE
7.7568643150723595
Annuals > 3 > ratios > PB
3.4273446241613668
Annuals > 3 > ratios > ROE
23.499909140468837
Annuals > 3 > ratios > ROA
12.914436366541505
Annuals > 3 > ratios > FCF
481500000
Annuals > 3 > ratios > Piotroski FScore
4
Annuals > 3 > ratios > fcf Percent
0.1605481644493348
Annuals > 3 > health Score
81
Valuation > metrics > PE
18.0719
Valuation > metrics > PB
2.2336560970419237
Valuation > final Score
100
Valuation > verdict
Fair
Profitability > metrics > ROE
9.303366200846517
Profitability > metrics > ROA
13.981331864539284
Profitability > metrics > Net Margin
0.18353665237938235
Profitability > final Score
76
Profitability > verdict
Adequate
Risk > metrics > Debt Equity
0.6148116620557565
Risk > metrics > Interest Coverage
40.796178343949045
Risk > final Score
88
Risk > verdict
Low
Liquidity > metrics > Current Ratio
3.1776196928635954
Liquidity > metrics > Quick Ratio
2.891260162601626
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
100
Prev Valuations > 1
100
Prev Valuations > 2
80
Prev Profitabilities > 0
54
Prev Profitabilities > 1
44
Prev Profitabilities > 2
50
Prev Risks > 0
88
Prev Risks > 1
88
Prev Risks > 2
68
Prev Liquidities > 0
100
Prev Liquidities > 1
98
Prev Liquidities > 2
98
Updated At
2026-01-20T22:02:41.928Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-02-12
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
AfterMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2021-03-31
Earnings History > 1 > report Date
2021-06-30
Earnings History > 1 > date
2021-03-31
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
EUR
Earnings History > 1 > eps Actual
2.1499
Earnings History > 1 > eps Estimate
0
Earnings History > 1 > eps Difference
2.1499
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2020-12-31
Earnings History > 2 > report Date
2021-03-31
Earnings History > 2 > date
2020-12-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
EUR
Earnings History > 2 > eps Actual
2.1252
Earnings History > 2 > eps Estimate
0
Earnings History > 2 > eps Difference
2.1252
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2020-09-30
Earnings History > 3 > report Date
2020-12-31
Earnings History > 3 > date
2020-09-30
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
EUR
Earnings History > 3 > eps Actual
2.3677
Earnings History > 3 > eps Estimate
0
Earnings History > 3 > eps Difference
2.3677
Earnings History > 3 > surprise Percent
-
Earnings History > 4 > period
2020-06-30
Earnings History > 4 > report Date
2020-09-30
Earnings History > 4 > date
2020-06-30
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
EUR
Earnings History > 4 > eps Actual
2.2727
Earnings History > 4 > eps Estimate
0
Earnings History > 4 > eps Difference
2.2727
Earnings History > 4 > surprise Percent
-
Earnings History > 5 > period
2020-03-31
Earnings History > 5 > report Date
2020-06-30
Earnings History > 5 > date
2020-03-31
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
EUR
Earnings History > 5 > eps Actual
1.4851
Earnings History > 5 > eps Estimate
0
Earnings History > 5 > eps Difference
1.4851
Earnings History > 5 > surprise Percent
-
Earnings History > 6 > period
2019-12-31
Earnings History > 6 > report Date
2020-03-31
Earnings History > 6 > date
2019-12-31
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
EUR
Earnings History > 6 > eps Actual
1.4565
Earnings History > 6 > eps Estimate
0
Earnings History > 6 > eps Difference
1.4565
Earnings History > 6 > surprise Percent
-
Earnings History > 7 > period
2019-09-30
Earnings History > 7 > report Date
2019-12-31
Earnings History > 7 > date
2019-09-30
Earnings History > 7 > before After Market
-
Earnings History > 7 > currency
EUR
Earnings History > 7 > eps Actual
-1.8276
Earnings History > 7 > eps Estimate
0
Earnings History > 7 > eps Difference
-1.8276
Earnings History > 7 > surprise Percent
-
Earnings History > 8 > period
2019-06-30
Earnings History > 8 > report Date
2019-09-30
Earnings History > 8 > date
2019-06-30
Earnings History > 8 > before After Market
-
Earnings History > 8 > currency
EUR
Earnings History > 8 > eps Actual
-1.776
Earnings History > 8 > eps Estimate
0
Earnings History > 8 > eps Difference
-1.776
Earnings History > 8 > surprise Percent
-
Earnings History > 9 > period
2019-03-31
Earnings History > 9 > report Date
2019-06-30
Earnings History > 9 > date
2019-03-31
Earnings History > 9 > before After Market
-
Earnings History > 9 > currency
EUR
Earnings History > 9 > eps Actual
1.4731
Earnings History > 9 > eps Estimate
0
Earnings History > 9 > eps Difference
1.4731
Earnings History > 9 > surprise Percent
-
Earnings History > 10 > period
2018-12-31
Earnings History > 10 > report Date
2019-03-31
Earnings History > 10 > date
2018-12-31
Earnings History > 10 > before After Market
-
Earnings History > 10 > currency
EUR
Earnings History > 10 > eps Actual
1.4531
Earnings History > 10 > eps Estimate
0
Earnings History > 10 > eps Difference
1.4531
Earnings History > 10 > surprise Percent
-
Earnings History > 11 > period
2018-09-30
Earnings History > 11 > report Date
2018-12-31
Earnings History > 11 > date
2018-09-30
Earnings History > 11 > before After Market
-
Earnings History > 11 > currency
EUR
Earnings History > 11 > eps Actual
1.3011
Earnings History > 11 > eps Estimate
0
Earnings History > 11 > eps Difference
1.3011
Earnings History > 11 > surprise Percent
-
Earnings History > 12 > period
2018-06-30
Earnings History > 12 > report Date
2018-09-30
Earnings History > 12 > date
2018-06-30
Earnings History > 12 > before After Market
-
Earnings History > 12 > currency
EUR
Earnings History > 12 > eps Actual
1.3185
Earnings History > 12 > eps Estimate
0
Earnings History > 12 > eps Difference
1.3185
Earnings History > 12 > surprise Percent
-
Earnings History > 13 > period
2018-03-31
Earnings History > 13 > report Date
2018-06-30
Earnings History > 13 > date
2018-03-31
Earnings History > 13 > before After Market
-
Earnings History > 13 > currency
EUR
Earnings History > 13 > eps Actual
1.3888
Earnings History > 13 > eps Estimate
0
Earnings History > 13 > eps Difference
1.3888
Earnings History > 13 > surprise Percent
-
Earnings History > 14 > period
2017-12-31
Earnings History > 14 > report Date
2018-03-31
Earnings History > 14 > date
2017-12-31
Earnings History > 14 > before After Market
-
Earnings History > 14 > currency
EUR
Earnings History > 14 > eps Actual
1.4651
Earnings History > 14 > eps Estimate
0
Earnings History > 14 > eps Difference
1.4651
Earnings History > 14 > surprise Percent
-
Earnings History > 15 > period
2017-09-30
Earnings History > 15 > report Date
2017-12-31
Earnings History > 15 > date
2017-09-30
Earnings History > 15 > before After Market
-
Earnings History > 15 > currency
EUR
Earnings History > 15 > eps Actual
1.049
Earnings History > 15 > eps Estimate
0
Earnings History > 15 > eps Difference
1.049
Earnings History > 15 > surprise Percent
-
Earnings History > 16 > period
2017-06-30
Earnings History > 16 > report Date
2017-09-30
Earnings History > 16 > date
2017-06-30
Earnings History > 16 > before After Market
-
Earnings History > 16 > currency
EUR
Earnings History > 16 > eps Actual
1.0334
Earnings History > 16 > eps Estimate
0
Earnings History > 16 > eps Difference
1.0334
Earnings History > 16 > surprise Percent
-
Earnings History > 17 > period
2017-03-31
Earnings History > 17 > report Date
2017-06-30
Earnings History > 17 > date
2017-03-31
Earnings History > 17 > before After Market
-
Earnings History > 17 > currency
EUR
Earnings History > 17 > eps Actual
0.857
Earnings History > 17 > eps Estimate
0
Earnings History > 17 > eps Difference
0.857
Earnings History > 17 > surprise Percent
-
Earnings History > 18 > period
2016-12-31
Earnings History > 18 > report Date
2017-03-31
Earnings History > 18 > date
2016-12-31
Earnings History > 18 > before After Market
-
Earnings History > 18 > currency
EUR
Earnings History > 18 > eps Actual
0.8005
Earnings History > 18 > eps Estimate
0
Earnings History > 18 > eps Difference
0.8005
Earnings History > 18 > surprise Percent
-
Earnings History > 19 > period
2016-09-30
Earnings History > 19 > report Date
2016-12-31
Earnings History > 19 > date
2016-09-30
Earnings History > 19 > before After Market
-
Earnings History > 19 > currency
EUR
Earnings History > 19 > eps Actual
0.5875
Earnings History > 19 > eps Estimate
0
Earnings History > 19 > eps Difference
0.5875
Earnings History > 19 > surprise Percent
-
Earnings History > 20 > period
2016-06-30
Earnings History > 20 > report Date
2016-09-30
Earnings History > 20 > date
2016-06-30
Earnings History > 20 > before After Market
-
Earnings History > 20 > currency
EUR
Earnings History > 20 > eps Actual
0.627
Earnings History > 20 > eps Estimate
0
Earnings History > 20 > eps Difference
0.627
Earnings History > 20 > surprise Percent
-
Earnings History > 21 > period
2016-03-31
Earnings History > 21 > report Date
2016-06-30
Earnings History > 21 > date
2016-03-31
Earnings History > 21 > before After Market
-
Earnings History > 21 > currency
EUR
Earnings History > 21 > eps Actual
0.896
Earnings History > 21 > eps Estimate
0
Earnings History > 21 > eps Difference
0.896
Earnings History > 21 > surprise Percent
-
Earnings History > 22 > period
2015-12-31
Earnings History > 22 > report Date
2016-03-31
Earnings History > 22 > date
2015-12-31
Earnings History > 22 > before After Market
-
Earnings History > 22 > currency
EUR
Earnings History > 22 > eps Actual
0.9189
Earnings History > 22 > eps Estimate
0
Earnings History > 22 > eps Difference
0.9189
Earnings History > 22 > surprise Percent
-
Earnings History > 23 > period
2015-09-30
Earnings History > 23 > report Date
2015-12-31
Earnings History > 23 > date
2015-09-30
Earnings History > 23 > before After Market
-
Earnings History > 23 > currency
EUR
Earnings History > 23 > eps Actual
0.6536
Earnings History > 23 > eps Estimate
0
Earnings History > 23 > eps Difference
0.6536
Earnings History > 23 > surprise Percent
-
Earnings History > 24 > period
2015-06-30
Earnings History > 24 > report Date
2015-09-30
Earnings History > 24 > date
2015-06-30
Earnings History > 24 > before After Market
-
Earnings History > 24 > currency
EUR
Earnings History > 24 > eps Actual
0.6716
Earnings History > 24 > eps Estimate
0
Earnings History > 24 > eps Difference
0.6716
Earnings History > 24 > surprise Percent
-
Earnings History > 25 > period
2015-03-31
Earnings History > 25 > report Date
2015-06-30
Earnings History > 25 > date
2015-03-31
Earnings History > 25 > before After Market
-
Earnings History > 25 > currency
EUR
Earnings History > 25 > eps Actual
0.6051
Earnings History > 25 > eps Estimate
0
Earnings History > 25 > eps Difference
0.6051
Earnings History > 25 > surprise Percent
-
Earnings History > 26 > period
2014-12-31
Earnings History > 26 > report Date
2015-03-31
Earnings History > 26 > date
2014-12-31
Earnings History > 26 > before After Market
-
Earnings History > 26 > currency
EUR
Earnings History > 26 > eps Actual
0.5835
Earnings History > 26 > eps Estimate
0
Earnings History > 26 > eps Difference
0.5835
Earnings History > 26 > surprise Percent
-
Earnings History > 27 > period
2014-09-30
Earnings History > 27 > report Date
2014-12-31
Earnings History > 27 > date
2014-09-30
Earnings History > 27 > before After Market
-
Earnings History > 27 > currency
EUR
Earnings History > 27 > eps Actual
0.3644
Earnings History > 27 > eps Estimate
0
Earnings History > 27 > eps Difference
0.3644
Earnings History > 27 > surprise Percent
-
Earnings History > 28 > period
2014-06-30
Earnings History > 28 > report Date
2014-09-30
Earnings History > 28 > date
2014-06-30
Earnings History > 28 > before After Market
-
Earnings History > 28 > currency
EUR
Earnings History > 28 > eps Actual
0.38
Earnings History > 28 > eps Estimate
0
Earnings History > 28 > eps Difference
0.38
Earnings History > 28 > surprise Percent
-
Earnings History > 29 > period
2014-03-31
Earnings History > 29 > report Date
2014-06-30
Earnings History > 29 > date
2014-03-31
Earnings History > 29 > before After Market
-
Earnings History > 29 > currency
EUR
Earnings History > 29 > eps Actual
0.8664
Earnings History > 29 > eps Estimate
0
Earnings History > 29 > eps Difference
0.8664
Earnings History > 29 > surprise Percent
-
Earnings History > 30 > period
2013-12-31
Earnings History > 30 > report Date
2014-03-31
Earnings History > 30 > date
2013-12-31
Earnings History > 30 > before After Market
-
Earnings History > 30 > currency
EUR
Earnings History > 30 > eps Actual
0.8697
Earnings History > 30 > eps Estimate
0
Earnings History > 30 > eps Difference
0.8697
Earnings History > 30 > surprise Percent
-
Earnings History > 31 > period
2013-09-30
Earnings History > 31 > report Date
2013-12-31
Earnings History > 31 > date
2013-09-30
Earnings History > 31 > before After Market
-
Earnings History > 31 > currency
EUR
Earnings History > 31 > eps Actual
0.4252
Earnings History > 31 > eps Estimate
0
Earnings History > 31 > eps Difference
0.4252
Earnings History > 31 > surprise Percent
-
Earnings History > 32 > period
2013-06-30
Earnings History > 32 > report Date
2013-09-30
Earnings History > 32 > date
2013-06-30
Earnings History > 32 > before After Market
-
Earnings History > 32 > currency
EUR
Earnings History > 32 > eps Actual
0.4179
Earnings History > 32 > eps Estimate
0
Earnings History > 32 > eps Difference
0.4179
Earnings History > 32 > surprise Percent
-
Earnings History > 33 > period
2013-03-31
Earnings History > 33 > report Date
2013-06-30
Earnings History > 33 > date
2013-03-31
Earnings History > 33 > before After Market
-
Earnings History > 33 > currency
EUR
Earnings History > 33 > eps Actual
0.6993
Earnings History > 33 > eps Estimate
0
Earnings History > 33 > eps Difference
0.6993
Earnings History > 33 > surprise Percent
-
Earnings History > 34 > period
2012-12-31
Earnings History > 34 > report Date
2013-03-31
Earnings History > 34 > date
2012-12-31
Earnings History > 34 > before After Market
-
Earnings History > 34 > currency
EUR
Earnings History > 34 > eps Actual
0.6906
Earnings History > 34 > eps Estimate
0
Earnings History > 34 > eps Difference
0.6906
Earnings History > 34 > surprise Percent
-
Earnings History > 35 > period
2012-03-31
Earnings History > 35 > report Date
2012-06-30
Earnings History > 35 > date
2012-03-31
Earnings History > 35 > before After Market
-
Earnings History > 35 > currency
EUR
Earnings History > 35 > eps Actual
0.7489
Earnings History > 35 > eps Estimate
0
Earnings History > 35 > eps Difference
0.7489
Earnings History > 35 > surprise Percent
-
Earnings History > 36 > period
2011-12-31
Earnings History > 36 > report Date
2012-03-31
Earnings History > 36 > date
2011-12-31
Earnings History > 36 > before After Market
-
Earnings History > 36 > currency
EUR
Earnings History > 36 > eps Actual
0.8005
Earnings History > 36 > eps Estimate
0
Earnings History > 36 > eps Difference
0.8005
Earnings History > 36 > surprise Percent
-
Earnings History > 37 > period
2011-09-30
Earnings History > 37 > report Date
2011-12-31
Earnings History > 37 > date
2011-09-30
Earnings History > 37 > before After Market
-
Earnings History > 37 > currency
EUR
Earnings History > 37 > eps Actual
-0.1484
Earnings History > 37 > eps Estimate
0
Earnings History > 37 > eps Difference
-0.1484
Earnings History > 37 > surprise Percent
-
Earnings History > 38 > period
2011-06-30
Earnings History > 38 > report Date
2011-09-30
Earnings History > 38 > date
2011-06-30
Earnings History > 38 > before After Market
-
Earnings History > 38 > currency
EUR
Earnings History > 38 > eps Actual
-0.1536
Earnings History > 38 > eps Estimate
0
Earnings History > 38 > eps Difference
-0.1536
Earnings History > 38 > surprise Percent
-
Earnings History > 39 > period
2011-03-31
Earnings History > 39 > report Date
2011-06-30
Earnings History > 39 > date
2011-03-31
Earnings History > 39 > before After Market
-
Earnings History > 39 > currency
EUR
Earnings History > 39 > eps Actual
0.7894
Earnings History > 39 > eps Estimate
0
Earnings History > 39 > eps Difference
0.7894
Earnings History > 39 > surprise Percent
-
Earnings History > 40 > period
2010-12-31
Earnings History > 40 > report Date
2011-03-31
Earnings History > 40 > date
2010-12-31
Earnings History > 40 > before After Market
-
Earnings History > 40 > currency
EUR
Earnings History > 40 > eps Actual
0.7666
Earnings History > 40 > eps Estimate
0
Earnings History > 40 > eps Difference
0.7666
Earnings History > 40 > surprise Percent
-
Earnings History > 41 > period
2010-09-30
Earnings History > 41 > report Date
2010-12-31
Earnings History > 41 > date
2010-09-30
Earnings History > 41 > before After Market
-
Earnings History > 41 > currency
EUR
Earnings History > 41 > eps Actual
0.1591
Earnings History > 41 > eps Estimate
0
Earnings History > 41 > eps Difference
0.1591
Earnings History > 41 > surprise Percent
-
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a inhibitor that is in phase III clinical trial for the treatment of second line follicular lymphoma; Tovorafenib that is in phase III clinical trial to treat first line pediatric Low-Grade Gliomas and is In phase II clinical trial for the treatment of relapsed/refractory pediatric Low-Grade Gliomas; and IPN01194 and IPN01195 that is in phase I to treat solid tumors. The company is also developing products for rare disease comprising Bylvay for the treatment of progressive familial intrahepatic cholestasis; Iqirvo, a peroxisome proliferator-activated receptor agonist to treat primary biliary cholangitis; NutropinAq, a liquid formulation of recombinant human growth hormone; Increlex, a recombinant human insulin-like growth factor; Fidrisertib that is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressive; Ritivixibat that is in phase II clinical trial to treat primary sclerosing cholangitis. In addition, it develops neuroscience products, such as Dysport that is in phase III clinical trial for the treatment of chronic and episodic migraine; and IPN10200 that is in phase II to treat aesthetic and therapeutic indications. The company has a partnership with Simcere Zaiming Pharmaceutical Co., Ltd. for the development of SIM0613, a protein expressed on varies tumor types and cancer-associated fibroblasts. The company was founded in 1929 and is headquartered in Paris, France.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AIpsen rises on FDA breakthrough therapy status for blood cancer therapy Seeking Alpha
Read more →Showing 2 of 9
(Last Updated 2025-06-30)
Health Score
Price to Earnings Ratio (P/E)
-
High
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Medium
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very High
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Medium
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Ipsen S.A
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
—
Date
2021-03-31
EPS Actual
2.1499
EPS Estimate
0
EPS Difference
2.1499
Surprise Percent
0%
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-06-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.